UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 11, 2022 the Board of Directors of CymaBay Therapeutics, Inc. appointed Charles McWherter, Ph.D. as President of Research and Development of CymaBay, effective as of November 1, 2022. As of the effective date of his appointment, Dr. McWherter’s salary on an annualized basis was increased to $490,000 and his target bonus for CymaBay’s annual discretionary bonus program was increased to 45% of his salary.
Charles McWherter, Ph.D., age 67, has served as CymaBay’s Senior Vice President and Chief Scientific Officer since 2013. From 2007 to 2013, he served as CymaBay’s Senior Vice President, Research and Preclinical Development. From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003, Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CymaBay Therapeutics, Inc. | ||
By: | /s/ Paul Quinlan | |
Name: | Paul Quinlan | |
Title: | General Counsel |
Dated: November 1, 2022
Document and Entity Information |
Oct. 11, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001042074 |
Document Type | 8-K |
Document Period End Date | Oct. 11, 2022 |
Entity Registrant Name | CymaBay Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36500 |
Entity Tax Identification Number | 94-3103561 |
Entity Address, Address Line One | 7575 Gateway Blvd. |
Entity Address, Address Line Two | Suite 110 |
Entity Address, City or Town | Newark |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94560 |
City Area Code | (510) |
Local Phone Number | 293-8800 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common stock, $0.0001 par value per share |
Trading Symbol | CBAY |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
UE(RDNNWPQ@%/8XIY'P05^ M[%'O)PRE7APH[NJ?90!9640RQ:RM1<2_[5P/A[BUU2L!Q1W[JQ+&\!12DR1Y M>K0UW4B%"[7M>VAM_Q3W[J6,12",2+?D"Q2X$BQNY,%5VGC\VOU]W*H7BA?I MX3##RJT/[!!A#_N\V32/7XM>*UGM^CYNT?\C>]0Z![)60%RV%?!DK]_BS#S( ME9U^U%^3E3!QX_1K$;$]A*46CD[!ZQ7YWKNQ&UJ2,45V+,XYR:"K.F(*1:[M MW\?]>J58:$MO>4C6LK'P6@3FL^D?&$EM]SYNS57R[M^"B*5;?G8KV2+T-%W> M37_%F&J?]R_R^?N$JZW-TD=0,)$MPHREC6>3%L&SM>:>G('M_PE?F'VC)C'? M@)!W,P!=51[1RX:167$L7DL#A^SB,N(,YH%] '[?2&G>&_:D7?U1,OD74$L# M!!0 ( .$P856?H!OPL0( .(, - >&PO
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end
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end